Pharmaceutical composition for treating children's hyperactivity

A technology for children with ADHD, composition, applied in the field of medicine

Active Publication Date: 2013-06-05
CHONGQING TECH & BUSINESS UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of this, the purpose of the present invention is to provide a pharmaceutical composition that can solve the problem of ADHD caused by children's brain neurodevelopment, and can improve the symptoms of ADHD, and achieve the purpose of "treating both symptoms and root causes".

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating children's hyperactivity
  • Pharmaceutical composition for treating children's hyperactivity
  • Pharmaceutical composition for treating children's hyperactivity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] In order to further understand the present invention, the present invention will be described in detail below in conjunction with examples. Embodiment 1: The influence of pharmaceutical composition of the present invention on norepinephrine content in rat brain tissue

[0018] Experimental animals: 36 healthy male SHR rats, aged 10 weeks, weighing 265-295 g, were purchased from the Institute of Experimental Animals, Sichuan Academy of Medical Sciences.

[0019] Grouping and administration: the rats were randomly divided into blank control group, atomoxetine hydrochloride group, atomoxetine hydrochloride and vitamin B6 groups with different ratios, 6 rats in each group, and administered by intragastric administration. The different ratios of atomoxetine hydrochloride and vitamin B6 and the atomoxetine hydrochloride group were both 10 mg / kg, and the blank control group was fed with equal doses of 0.9% NaCl every morning, once a day, for 14 consecutive days. During the ex...

Embodiment 2

[0024] Embodiment 2: The influence of pharmaceutical composition of the present invention on rat brain tissue neuron injury repair

[0025]Experimental animals: Wistar rats, within 48 hours of birth, were purchased from the Institute of Experimental Animals, Sichuan Academy of Medical Sciences.

[0026] Cell culture: Wistar rats born within 48 hours were taken out, sterilized, and the cerebral cortex was isolated under aseptic conditions, washed twice with PBS solution, and digested in 0.25% trypsin for 30 minutes. Use a pipette to discard surface trypsin. Add DMEM high-glucose culture medium containing 10% fetal bovine serum, centrifuge at 1000r / min for 3min, and discard the supernatant to make a single-cell suspension. After natural sedimentation, transfer the upper single-cell suspension to another centrifuge tube, repeat the same method, and finally obtain the cell suspension. Inoculated in pre-placed 6-well culture plate, placed at 37°C, 5% CO 2 cultured in an incubato...

Embodiment 3

[0032] Embodiment 3: the tablet for treating ADHD in children

[0033] Formula composition (calculated on the basis of 1000 tablets)

[0034]

[0035] Preparation method Weigh atomoxetine hydrochloride, vitamin B6, mannitol, starch, magnesium stearate, and micropowder silica gel, mix well, add appropriate amount of distilled water, stir and granulate, pass through a 20-mesh sieve, dry, and compress into tablets, about 0.3g per tablet .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicines and specifically to a pharmaceutical composition for treating children's hyperactivity. The pharmaceutical composition for treating children's hyperactivity in the invention comprises tomoxetine hydrochloride and vitamin B6, and the mass ratio of tomoxetine hydrochloride to vitamin B6 is 1: 0.5 to 1:4; tomoxetine hydrochloride and vitamin B6 can be compounded with normal accessories to prepare a medicine for treating children's hyperactivity. According to the invention, composition of tomoxetine hydrochloride and vitamin B6 which weighs 0.5 to 4times of tomoxetine hydrochloride has a synergistic effect, can substantially enhance the upturning effect of NA, promote the development of brain nerves and stabilizing the functions of brain cells,and produces an effect of simultaneous treatment of principal and subordinate symptoms on children's hyperactivity.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical composition for treating ADHD in children. Background technique [0002] ADHD, also known as attention deficit hyperactivity disorder (ADHD), or mild brain dysfunction syndrome, is a common disorder of children's behavior, causing children to behave abnormally. According to foreign reports, the prevalence of ADHD in children is between 5% and 10%, and domestic surveys are above 10%. Premature infants have the highest probability of suffering from ADHD, about 60%, and boys are far more than girls. Children with ADHD have normal or basically normal intelligence, but have defects in learning, behavior and emotion, mainly manifested as inattention, short-term attention, excessive activity, emotional impulsiveness, generally poor academic performance, poor performance in family and school It is difficult to get along with others, and often makes parents and teachers feel help...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4415A61P25/00A61K31/138
Inventor 汪程远郑旭煦殷钟意陈刚
Owner CHONGQING TECH & BUSINESS UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap